XCXiang-Qi Chen

Xiang-Qi Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiang-Qi Chen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Sheng Yang

    Fujian Medical University Union Hospital

    3 shared publications
  • Fan Yang

    Department of Respiratory and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, People’s Republic of China

    2 shared publications
  • Pei-Lin Guo

    Department of Respiratory and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, People’s Republic of China

    2 shared publications
  • Qiong Luo

    Department of Oncology Medicine, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, People’s Republic of China

    2 shared publications
  • Tingyan Lin

    Department of Respiratory Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China

    2 shared publications
  • Xiao-Yun Chen

    Department of Respiratory and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, People’s Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Clinical features and prognosis of advanced intra- and extra-pulmonary neuroendocrine carcinomas

    by Xiao-Yun Chen, Ning-Jing Guo, Pei-Lin Guo, Fan Yang, Qiong Luo, Sheng Yang, Xiang-Qi Chen

    Objective: We examined the clinical features and prognosis of advanced intra- and extra-pulmonary neuroendocrine carcinomas (NECs) to offer additional guidance for the clinical treatment of small-cell lung cancer (SCLC), which is a type of advanced intrapulmonary NEC (IPNECs). Materials and Methods: The clinical data and survival of 123 patients with advanced IPNECs and extrapulmonary NECs (EPNECs) were obtained. We retrospectively examined the corresponding clinical diagnosis and treatment and investigated the significant factors influencing the survival prognosis of patients with NECs. Results: There were 90 cases of IPNECs (including 81 cases of SCLC), and 33 cases of EPNECs. The median overall survival (OS) of IPNECs was significantly longer than that of the EPNECs in the gastrointestinal tract and in the other regions (P < 0.05). The median OS of patients with other IPNECs was longer than that of patients with SCLC (P > 0.05). Multivariate analysis demonstrated that age, liver metastasis, number of cycles of first-line chemotherapy, and chest radiotherapy were risk factors influencing OS in patients with NECs (P < 0.05). Conclusions: The survival of IPNECs was significantly longer than that of EPNECs in the gastrointestinal tract and other regions. Nevertheless, patients with advanced NECs who were older and had liver metastases had a poorer prognosis. Multidisciplinary treatments including multicycle chemotherapy and a combination of chemotherapy and radiotherapy should function significantly in extending the survival of NECs.


  • Open Access

    Risk factors and prognostic factors for pulmonary large cell neuroendocrine carcinoma with brain metastasis

    by Xiaoyun Chen, Yedong Huang, Fangrong Chen, Hui She, Xiangqi Chen

    Background: As the studies regarding the brain metastasis (BM) of pulmonary large cell neuroendocrine carcinoma (LCNEC) are insufficient, the present research aims to describe the risk factors and prognostic factors that are related to cancer‐specific survival (CSS) for LCNEC patients with BM.Methods: The data of LCNEC patients between January 2010 and October 2018 were obtained from the SEER database. Binary logistic regression analyses were utilized to screen the possible risk factors related to BM. Prognostic factors for LCNEC patients with BM were indentified by Cox regression analyses. Moreover, a nomogram was established to predict the 6‐, 12‐, and 18‐month CSS rates. The concordance index (C‐index), receiver operating characteristic (ROC) curves and calibration curves were utilized to assess the discrimination and reliability of the model. Clinical decision curves (DCAs) were used to evaluate the clinical benefits and utility of our model.Results: Totally, 1875 patients were enrolled, with 294 (15.7%) of them having BM at diagnosis. Multivariate logistic regression analyses revealed that patients with age < 65 (odds ratio, OR = 1.564) and N2 staging (OR = 1.775) had a greater chance of developing BM. Age (≥ 65 vs. < 65: hazard ratio, HR = 1.409), T staging (T1 vs. T0: HR = 4.580; T2 vs. T0: HR = 6.008; T3 vs. T0: HR = 7.065; T4 vs. T0: HR = 6.821), N staging (N2 vs. N0: HR = 1.592; N3 vs. N0: HR = 1.654), liver metastasis (HR = 1.410), primary site surgery (HR = 0.581) and chemotherapy (HR = 0.452) were independent prognostic factors for LCNEC patients with BM. A nomogram prediction model was constructed by incorporating these factors. Using the C‐index, calibration curves, ROC curves, and DCAs, we found that the clinical prediction model performed well.Conclusion: We described the risk factors and prognostic factors that were associated with CSS for LCNEC patients with BM. The related nomogram was established and validated to help clinicians formulate more rational and effective treatment strategies.


  • Open Access

    Clinical Features And Prognosis of Advanced Intra- And Extra-Pulmonary Neuroendocrine Carcinomas

    by Xiao-Yun Chen, Pei-Lin Guo, Fan Yang, Qiong Luo, Sheng Yang, Xiang-Qi Chen

    Objective: We analyzed the clinical features and prognosis of advanced intra- and extra-pulmonary neuroendocrine carcinomas (NECs) in order to provide further guidance for the clinical treatment of small-cell lung cancer, which is a type of advanced intrapulmonary NECs. Methods: The clinical data and survival of 123 patients with advanced intra- and extra-pulmonary NECs in the Fujian Medical University Union Hospital, Fujian Province, China, between January 2013 to November 2019 were collected. We retrospectively analyzed the corresponding clinical diagnosis and treatment, and explored the relevant factors affecting the survival prognosis of patients with intra- and extra-pulmonary NECs. Results: The data of 123 patients were collected. There were 90 cases of intra-pulmonary NECS (including 81 cases of small-cell lung cancer, SCLC), 25 cases of extra-pulmonary NECs involving in the gastrointestinal tract, and 8 cases of extra-pulmonary NECs in other regions. The median overall survival (OS) of intra-pulmonary NECs was 13.53 months, of which the median OS of SCLC was 12.97 months, and the median OS of other intra-pulmonary NECs was 27.07 months. The median OS of extra-pulmonary NECs in the gastrointestinal tract was 9.42 months, and the OS of extra-pulmonary NECs in the other regions was 8.69 months. The median OS of intra-pulmonary NECs was significantly longer than that of the extra-pulmonary NECs in the gastrointestinal tract and in the other regions (P < 0.05). Multivariate analysis showed that age, liver metastasis, number of cycles of first-line chemotherapy, and chest radiotherapy were risk factors affecting OS in patients with NECs (P < 0.05). Conclusions: The survival of intra-pulmonary NECs was significantly longer than that of extra-pulmonary NECs of the gastrointestinal tract and in other regions. However, patients with advanced intra- and extra-pulmonary NECs who were older and had liver metastases had a poorer prognosis. Multi-disciplinary treatments such as multi-cycle chemotherapy and combination of chemotherapy and radiotherapy should play an important role in prolonging the survival of NECs.

  • Open Access

    Lactate dehydrogenase elevations is associated with severity of COVID-19: a meta-analysis

    by Xiao-Yun Chen, Ming-Yao Huang, Zheng-Wei Xiao, Sheng Yang, Xiang-Qi Chen


  • Open Access

    Effect and mechanism of miR‑146a on malignant biological behaviors of lung adenocarcinoma cell line

    by Fang Yuan, Suyun Zhang, Wenying Xie, Sheng Yang, Tingyan Lin, Xiangqi Chen

    The aim of the present study was to assess the expression of microRNA‑146a (miR‑146a) in human lung adenocarcinoma cells, its effect on cellular behaviors, and the underlying molecular mechanisms. Reverse transcription‑quantitative PCR (RT‑qPCR) was used to measure miR‑146a expression in the human normal lung epithelial cell line, BEAS‑2B, and human lung adenocarcinoma cell lines, A549, PC‑9 and H1299, to determine whether miR‑146a acts as an oncogene or anti‑oncogene. miR‑146a mimics were transfected into target cells to observe the proliferation, apoptosis, invasion and migration of human lung adenocarcinoma cells. The target genes of miR‑146a were predicted using bioinformatics analysis, and binding sites were validated by dual‑luciferase reporter assay. Target gene expression at the mRNA and protein levels was measured by RT‑qPCR and western blot analysis, respectively. The expression levels of miR‑146a in human lung adenocarcinoma cell lines were lower than its expression in BEAS‑2B (P<0.01). A549 cell line is a EGFR wild‑type lung adenocarcinoma cell line, which is also the most widely studied in NSCLC, and therefore this was chosen as the target cell line for further investigation. Overexpression of miR‑146a in A549 cells can inhibit cell proliferation (P<0.05), promote apoptosis (P<0.05), and reduce the cells' migratory ability (P<0.01). Bioinformatics prediction indicated that interleukin‑1 receptor‑associated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6) are the target genes of miR‑146a. Dual‑luciferase reporter assay showed that miR‑146a could specifically bind to 3'‑untranslated regions of IRAK1 and TRAF6. The protein and mRNA levels of IRAK1 and TRAF6 were significantly downregulated after miR‑146a overexpression in A549 cells (P<0.01). The results of this study demonstrated that the expression of miR‑146a in human lung adenocarcinoma cells was significantly lower than in normal lung epithelial cells, indicating that miR‑146a acts as an anti‑oncogene. miR‑146a suppresses the proliferation and migration of human lung adenocarcinoma cells by downregulating the expression of IRAK1 and TRAF6.


  • Antitumor activity of interleukin-18 on A549 human lung cancer cell line

    by Xiangqi Chen, Donglan Xiong, Rui Feng, Sheng Yang, Tingyan Lin

    Objective: In this study, we investigated the antitumor activity of interleukin (IL)-18 on A549 human lung cancer cell line and evaluated the potential of IL-18 therapy in lung cancer. Materials and Methods: We generated a human IL-18 lentiviral expression vector and examined three groups of A549 cells, including nontransduced cells and cells transduced with either IL-18 or an empty lentiviral expression vector. IL-18 expression, cell proliferation, and apoptosis were examined using Western blotting, methylthiazolyldiphenyl-tetrazolium bromide assay, and flow cytometry, respectively. The expression of the T helper 1 (Th1) cytokine interferon-γ (IFN-γ) and Th2 cytokine IL-4 was analyzed by enzyme-linked immunosorbent assay (ELISA). Results: Compared to the other groups of cells, A549 cells transduced with the IL-18 lentiviral expression vector exhibited significant increases in IL-18 expression, apoptosis, and the fraction of cells in G0 and G1 phases of the cell cycle and significant decrease in proliferation. Furthermore, ELISA results showed that IFN-γ expression increased significantly and IL-4 decreased in A549 cells transfected with IL-18 lentivirus expression vector. Conclusion: Using a lentiviral expression vector, IL-18 was expressed stably and efficiently in A549 cells, which showed attenuated proliferation and tumor cell growth, and enhanced tumor cell apoptosis. IL-18 expression also induced the secretion of IFN-γ, while decreasing the production of IL-4, therefore restoring the balance between Th1/Th2 cell subsets. These findings further demonstrated the antitumor activity of IL-18 and might open new therapeutic avenues for the prevention and treatment of lung cancer.